{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:30:16Z","timestamp":1771036216474,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T00:00:00Z","timestamp":1619136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00392-021-01853-8","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T03:23:09Z","timestamp":1619320989000},"page":"380-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial"],"prefix":"10.1007","volume":"111","author":[{"given":"Pieter","family":"Martens","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"John","family":"Vincent","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Abreu","sequence":"additional","affiliation":[]},{"given":"Martijn","family":"Busselen","sequence":"additional","affiliation":[]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[]},{"given":"Wilson W. H.","family":"Tang","sequence":"additional","affiliation":[]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"1853_CR1","first-page":"e5673","volume":"11","author":"V Shah","year":"2019","unstructured":"Shah V, Jahan N (2019) Prognostic significance of hyponatremia in ST-elevation myocardial infarction\/heart failure patients. Cureus 11:e5673","journal-title":"Cureus"},{"key":"1853_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s00392-018-1268-5","volume":"107","author":"Y Plakht","year":"2018","unstructured":"Plakht Y, Gilutz H, Shiyovich A (2018) Sodium levels during hospitalization with acute myocardial infarction are markers of in-hospital mortality: Soroka acute myocardial infarction II (SAMI-II) project. Clin Res Cardiol 107:956\u2013964","journal-title":"Clin Res Cardiol"},{"key":"1853_CR3","doi-asserted-by":"publisher","first-page":"e7023","DOI":"10.1097\/MD.0000000000007023","volume":"96","author":"JS Choi","year":"2017","unstructured":"Choi JS, Kim CS, Bae EH et al (2017) Prognostic impact of hyponatremia occurring at various time points during hospitalization on mortality in patients with acute myocardial infarction. Medicine (Baltimore) 96:e7023","journal-title":"Medicine (Baltimore)"},{"key":"1853_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1177\/2047487314557963","volume":"22","author":"K Burkhardt","year":"2015","unstructured":"Burkhardt K, Kirchberger I, Heier M et al (2015) Hyponatraemia on admission to hospital is associated with increased long-term risk of mortality in survivors of myocardial infarction. Eur J Prev Cardiol 22:1419\u20131426","journal-title":"Eur J Prev Cardiol"},{"key":"1853_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.cardfail.2013.09.004","volume":"19","author":"L Balling","year":"2013","unstructured":"Balling L, Kober L, Schou M, Torp-Pedersen C, Gustafsson F (2013) Efficacy and safety of angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and hyponatremia. J Card Fail 19:725\u2013730","journal-title":"J Card Fail"},{"key":"1853_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.amjcard.2012.07.004","volume":"110","author":"C Lazzeri","year":"2012","unstructured":"Lazzeri C, Valente S, Chiostri M, Attana P, Picariello C, Gensini GF (2012) Usefulness of hyponatremia in the acute phase of ST-elevation myocardial infarction as a marker of severity. Am J Cardiol 110:1419\u20131424","journal-title":"Am J Cardiol"},{"key":"1853_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/CIRCHEARTFAILURE.111.961011","volume":"4","author":"VD Madan","year":"2011","unstructured":"Madan VD, Novak E, Rich MW (2011) Impact of change in serum sodium concentration on mortality in patients hospitalized with heart failure and hyponatremia. Circ Heart Fail 4:637\u2013643","journal-title":"Circ Heart Fail"},{"key":"1853_CR8","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","volume":"111","author":"L Klein","year":"2005","unstructured":"Klein L, O\u2019Connor CM, Leimberger JD et al (2005) Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF) study. Circulation 111:2454\u20132460","journal-title":"Circulation"},{"key":"1853_CR9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1681\/ASN.2007070752","volume":"19","author":"AM Shea","year":"2008","unstructured":"Shea AM, Hammill BG, Curtis LH, Szczech LA, Schulman KA (2008) Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 19:764\u2013770","journal-title":"J Am Soc Nephrol"},{"key":"1853_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/j.1365-2362.2011.02532.x","volume":"41","author":"M Schou","year":"2011","unstructured":"Schou M, Valeur N, Torp-Pedersen C, Gustafsson F, Kober L (2011) Plasma sodium and mortality risk in patients with myocardial infarction and a low LVEF. Eur J Clin Invest 41:1237\u20131244","journal-title":"Eur J Clin Invest"},{"key":"1853_CR11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/eurjhf\/hfr086","volume":"13","author":"L Balling","year":"2011","unstructured":"Balling L, Schou M, Videbaek L, Hildebrandt P, Wiggers H, Gustafsson F (2011) Prevalence and prognostic significance of hyponatraemia in outpatients with chronic heart failure. Eur J Heart Fail 13:968\u2013973","journal-title":"Eur J Heart Fail"},{"key":"1853_CR12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.amjmed.2016.01.016","volume":"129","author":"FH Verbrugge","year":"2016","unstructured":"Verbrugge FH, Grodin JL, Mullens W, Taylor DO, Starling RC, Tang WH (2016) Transient hyponatremia during hospitalization for acute heart failure. Am J Med 129:620\u2013627","journal-title":"Am J Med"},{"key":"1853_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1681\/ASN.2008020143","volume":"19","author":"RA Hirth","year":"2008","unstructured":"Hirth RA, Messana JM (2008) What does a serum sodium cost? J Am Soc Nephrol 19:654\u2013655","journal-title":"J Am Soc Nephrol"},{"key":"1853_CR14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jacc.2014.12.010","volume":"65","author":"FH Verbrugge","year":"2015","unstructured":"Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WH, Mullens W (2015) Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol 65:480\u2013492","journal-title":"J Am Coll Cardiol"},{"key":"1853_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J 37:2129\u20132200","journal-title":"Eur Heart J"},{"issue":"14","key":"1853_CR16","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2020","unstructured":"Collet JP, Thiele H, Barbato E et al 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289\u20131367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"key":"1853_CR17","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321","journal-title":"N Engl J Med"},{"key":"1853_CR18","doi-asserted-by":"publisher","first-page":"e006597","DOI":"10.1161\/CIRCHEARTFAILURE.119.006597","volume":"13","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Eschalier R, Duarte K et al (2020) Reduced diuretic dose in patients treated with eplerenone: data from the EPHESUS trial. Circ Heart Fail 13:e006597","journal-title":"Circ Heart Fail"},{"key":"1853_CR19","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","volume":"28","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Abraham WT, Albert NM et al (2007) Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the optimize-HF registry. Eur Heart J 28:980\u2013988","journal-title":"Eur Heart J"},{"key":"1853_CR20","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","volume":"113","author":"WC Levy","year":"2006","unstructured":"Levy WC, Mozaffarian D, Linker DT et al (2006) The Seattle heart failure model: prediction of survival in heart failure. Circulation 113:1424\u20131433","journal-title":"Circulation"},{"key":"1853_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.7326\/0003-4819-100-6-782","volume":"100","author":"M Packer","year":"1984","unstructured":"Packer M, Medina N, Yushak M (1984) Correction of dilutional hyponatremia in severe chronic heart failure by converting-enzyme inhibition. Ann Intern Med 100:782\u2013789","journal-title":"Ann Intern Med"},{"key":"1853_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJM198402093100603","volume":"310","author":"VJ Dzau","year":"1984","unstructured":"Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH (1984) Prostaglandins in severe congestive heart failure. Relation to activation of the renin\u2014angiotensin system and hyponatremia. N Engl J Med 310:347\u2013352","journal-title":"N Engl J Med"},{"key":"1853_CR23","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/eurheartj\/ehx035","volume":"38","author":"W Mullens","year":"2017","unstructured":"Mullens W, Verbrugge FH, Nijst P, Tang WHW (2017) Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J 38:1872\u20131882","journal-title":"Eur Heart J"},{"key":"1853_CR24","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","volume":"1","author":"SR Goldsmith","year":"1983","unstructured":"Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1:1385\u20131390","journal-title":"J Am Coll Cardiol"},{"key":"1853_CR25","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1152\/ajplegacy.1959.196.4.927","volume":"196","author":"CW Gottschalk","year":"1959","unstructured":"Gottschalk CW, Mylle M (1959) Micropuncture study of the mammalian urinary concentrating mechanism: evidence for the countercurrent hypothesis. Am J Physiol 196:927\u2013936","journal-title":"Am J Physiol"},{"key":"1853_CR26","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.amjcard.2014.03.017","volume":"113","author":"C Bavishi","year":"2014","unstructured":"Bavishi C, Ather S, Bambhroliya A et al (2014) Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions. Am J Cardiol 113:1834\u20131838","journal-title":"Am J Cardiol"},{"key":"1853_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.amjcard.2004.04.059","volume":"94","author":"W Sligl","year":"2004","unstructured":"Sligl W, McAlister FA, Ezekowitz J, Armstrong PW (2004) Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol 94:443\u2013447","journal-title":"Am J Cardiol"},{"key":"1853_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.1973.03220280028007","volume":"225","author":"DJ Greenblatt","year":"1973","unstructured":"Greenblatt DJ, Koch-Weser J (1973) Adverse reactions to spironolactone. A report from the Boston collaborative drug surveillance program. JAMA 225:40\u201343","journal-title":"JAMA"},{"key":"1853_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/ejhf.1369","volume":"21","author":"W Mullens","year":"2019","unstructured":"Mullens W, Damman K, Harjola VP et al (2019) The use of diuretics in heart failure with congestion\u2014a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail 21:137\u2013155","journal-title":"Eur J Heart Fail"},{"key":"1853_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/01.CIR.73.2.257","volume":"73","author":"WH Lee","year":"1986","unstructured":"Lee WH, Packer M (1986) Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 73:257\u2013267","journal-title":"Circulation"},{"key":"1853_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/0002-9149(92)91194-9","volume":"70","author":"S Ljungman","year":"1992","unstructured":"Ljungman S, Kjekshus J, Swedberg K (1992) Renal function in severe congestive heart failure during treatment with enalapril [the cooperative North Scandinavian enalapril survival study (CONSENSUS) Trial]. Am J Cardiol 70:479\u2013487","journal-title":"Am J Cardiol"},{"key":"1853_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/ejhf.1697","volume":"22","author":"W Mullens","year":"2020","unstructured":"Mullens W, Damman K, Testani JM et al (2020) Evaluation of kidney function throughout the heart failure trajectory\u2014a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail 22:584\u2013603","journal-title":"Eur J Heart Fail"},{"key":"1853_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","volume":"7","author":"O Vardeny","year":"2014","unstructured":"Vardeny O, Claggett B, Anand I et al (2014) Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7:573\u2013579","journal-title":"Circ Heart Fail"},{"key":"1853_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"S Yusuf","year":"1992","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685\u2013691","journal-title":"N Engl J Med"},{"key":"1853_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","volume":"65","author":"J Bauersachs","year":"2015","unstructured":"Bauersachs J, Jaisser F, Toto R (2015) Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 65:257\u2013263","journal-title":"Hypertension"},{"key":"1853_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.111.065391","volume":"125","author":"CP Kovesdy","year":"2012","unstructured":"Kovesdy CP, Lott EH, Lu JL et al (2012) Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 125:677\u2013684","journal-title":"Circulation"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01853-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01853-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01853-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:11:02Z","timestamp":1648717862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01853-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01853-8","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,23]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see  for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (a) for indications that have been approved in the US and\/or EU or (b) in programs that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24\u00a0months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing policy"}}]}}